A randomised study of rituximab and belimumab sequential therapy in pr3 anca-associated vasculitis (combivas): design of the study protocol

HIGHLIGHTS

• who: Mark McClure from the (UNIVERSITY) have published the research work: A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol, in the Journal: (JOURNAL) of May/30,/2019

SUMMARY

Administrative information Title A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol Trial registration ClinicalTrials.gov Identifier: NCT03967925, May 30, 2019 Protocol version @@

ACRONYMS

• COMBIVAS: Associated vasculitis

LAY DEFINITIONS

• rituximab: A monoclonal antibody (mAb . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.